SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing significant community backlash as investors express frustration over a potential reverse stock split and ongoing share dilution, despite the company's recent commercial launch of its fibromyalgia treatment and notable insider buying from the CEO. While some retail shareholders are aggressively voting against further dilution, others view the current price as a value opportunity based on growing prescription data and expanding insurance coverage.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is seeing intense market volatility driven by regional instability, which has impacted jet fuel costs and commercial aviation sentiment, while simultaneously highlighting the strategic importance of its defense contracts and Small Modular Reactor (SMR) initiatives. Investors remain deeply divided, with some concerned about near-term price swings and geopolitical exposure, while others are actively using the dip to accumulate shares, citing long-term value from ongoing share buybacks, strong balance sheet ratings, and a robust backlog of government and defense orders.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorth Holdings is trending as investors transition from the Armada Acquisition Corp SPAC to the XRPN ticker, with the community actively debating the potential of this crypto treasury model. Market participants are focused on accumulating shares and warrants while speculating on how the entity will eventually decouple from broader market volatility and align with XRP price performance.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is experiencing heightened community debate as investors weigh strong dividend yields and favorable technical setups against ongoing concerns over pipeline growth and regulatory headwinds from potential pharmaceutical tariffs. While some traders are focused on short-term option signals and a possible breakout above key resistance, others remain skeptical, pointing to the company's historical performance and the competitive pressure in the obesity and oncology markets.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is experiencing heightened market activity driven by institutional partnerships with industry leaders and ongoing development of its decentralized agent network, sparking debate within the community regarding its long-term utility versus recent supply-related performance struggles. Traders are closely monitoring key technical support and resistance levels as the token attempts to navigate current market volatility and consolidate for potential future growth.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to a combination of strong earnings performance and significant anticipation surrounding upcoming late-breaking clinical data for the CHOPIN trial at ESMO. While the community is actively debating the company's aggressive investment into R&D for new indications versus near-term profitability, sentiment remains bullish among many investors who view current price volatility as a potential accumulation opportunity ahead of further clinical catalysts.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is facing intense scrutiny from the community, with polarized debates focusing on its underperformance compared to other assets and skepticism surrounding the impact of the newly launched LitVM testnet. While some investors view current price levels as an accumulation opportunity ahead of potential long-term technological adoption, others remain vocal about the asset's persistent stagnation and lack of significant market momentum.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp Developments is trending due to heightened institutional interest and positive technical patterns as the company advances its Elk Creek project. The community is actively discussing the potential impact of long-awaited feasibility study results and imminent debt financing, with many investors weighing these upcoming catalysts against past timeline delays.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is currently trending as investors anticipate the PDUFA date for its lead AML treatment, ziftomenib, while closely watching the company's progress following a recent $30 million milestone payment and positive clinical trial momentum. Community discussion centers on the potential for ziftomenib to become a best-in-class, once-daily therapy, with many active investors highlighting its strong cash position and clinical synergy relative to competitors in the oncology space.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as it establishes itself as a critical U.S.-based player in the rare earth supply chain, with investors focused on its defense-aligned metallization facility and recent government contracts that reduce reliance on Chinese supply. The community is actively discussing the company's high-profile advisory board, recent analyst coverage, and its strategic importance to Western defense procurement mandates, while balancing excitement over its growth potential against ongoing debates regarding dilution and its pre-revenue status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


southsidewreckers1

southsideWreckers